AI in Science: Real Progress, Not Utopia Yet

What the sources actually confirm

I would not dismiss this wave of advances as fantasy, but it is also too early to assemble them into a ready-made utopia. As of August 2026, verified research shows genuine progress in oncology, mathematics and robotics. Still, the scale of public claims clearly exceeds the published evidence.

The strongest signal comes from medicine. An npj Precision Oncology publication on the PRECISE CURATE.AI clinical study describes testing dynamically personalized chemotherapy dosing recommendations for patients with advanced solid tumors. This is a feasibility study, not proof of a ready-to-use personalized cancer cure—let alone a cure for late-stage disease.

The picture is broader than a single trial. A 2025 systematic review in Artificial Intelligence in Medicine covered 72 studies of AI applications in oncology trials. An analysis of the ClinicalTrials.gov registry published in Cancers identified 50 completed studies, 66% of them interventional. This is translational work, not merely an impressive demo.

In pure mathematics, the evidence is more modest than the headlines. The 2025 preprint Advancing Mathematical Research via Human-AI Interactive Theorem Proving confirms progress in collaborative theorem proving between humans and AI. But the publications reviewed do not independently substantiate claims about a new rank-30 elliptic curve or ten previously inaccessible theorems solved every day.

Robotics looks similar. The ICCV 2025 workshop paper LLMs as NAO Robot 3D Motion Planners demonstrated motion-planning control through a language model, with results statistically above random. Apple’s 2026 MIA-Bench report expands the evaluation of instruction following, but neither document confirms a universal robot model that can perform any action from a prompt.

Where the real shift is happening

The key change has already occurred: generative AI is becoming a working layer between researchers and complex domain systems. In oncology, it helps personalize decisions; in mathematics, it supports proof search; in robotics, it translates natural language into action plans.

Yet these fields have very different levels of maturity. I would first examine clinical endpoints, formal proof verification and a robot’s robustness beyond a controlled benchmark. That is where elegant results most often meet reality: generalizability, reasoning errors and the physical world.

The progress is real. Utopia begins when a feasibility study, a mathematical assistant and a laboratory prototype are presented as fully solved problems.

We previously examined embodied AI through an RPi case, separating robotics demonstrations from the architecture needed to make them work. That distinction helps frame what general-purpose robotics breakthroughs actually require.